BioCardia to Host Q2 2024 Corporate Update and Financial Results Conference Call on August 13, 2024
BioCardia (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, has announced its Q2 2024 corporate update and financial results conference call. The call is scheduled for August 13, 2024, at 4:30 PM ET. Participants can register online or dial in to join the call. For U.S. callers, the number is 1-833-316-0559, while international callers should use 1-412-317-5730. A live webcast will also be available. Replay options include a webcast replay and a telephonic replay accessible with specific access codes. This event provides an opportunity for investors and analysts to gain insights into BioCardia's recent performance and future outlook.
BioCardia (NASDAQ:BCDA), un sviluppatore di terapie cellulari e derivate per malattie cardiovascolari e polmonari, ha annunciato la conference call per l'aggiornamento aziendale e i risultati finanziari del secondo trimestre 2024. La chiamata è programmata per 13 agosto 2024, alle 16:30 ET. I partecipanti possono registrarsi online oppure chiamare per unirsi alla conversazione. Per i chiamanti negli Stati Uniti, il numero è 1-833-316-0559, mentre i chiamanti internazionali dovrebbero utilizzare 1-412-317-5730. Sarà disponibile anche una diretta streaming. Le opzioni di replay includono una registrazione della diretta e una registrazione telefonica accessibili con codici di accesso specifici. Questo evento offre un'opportunità per investitori e analisti di ottenere informazioni sulle recenti performance di BioCardia e sulle prospettive future.
BioCardia (NASDAQ:BCDA), un desarrollador de terapias celulares y derivadas para enfermedades cardiovasculares y pulmonares, ha anunciado su actualización corporativa y la conferencia telefónica sobre resultados financieros del segundo trimestre de 2024. La llamada está programada para 13 de agosto de 2024, a las 4:30 PM ET. Los participantes pueden registrarse en línea o llamar para unirse a la llamada. Para los que llaman desde EE.UU., el número es 1-833-316-0559, mientras que los llamadores internacionales deben usar 1-412-317-5730. También estará disponible una retransmisión en vivo. Las opciones de repetición incluyen una retransmisión web y una repetición telefónica accesibles con códigos de acceso específicos. Este evento brinda la oportunidad a los inversores y analistas de obtener información sobre el rendimiento reciente de BioCardia y sus perspectivas futuras.
BioCardia (NASDAQ:BCDA)는 심혈관 및 폐 질환을 위한 세포 및 세포 유래 치료제를 개발하는 회사로, 2024년 2분기 기업 업데이트 및 재무 결과에 대한 컨퍼런스 콜을 발표했습니다. 이 통화는 2024년 8월 13일 오후 4:30 ET에 예정되어 있습니다. 참가자는 온라인으로 등록하거나 전화로 참여할 수 있습니다. 미국에서 전화하는 경우, 번호는 1-833-316-0559이며, 국제 전화자는 1-412-317-5730을 사용해야 합니다. 실시간 웹캐스트도 이용 가능합니다. 재생 옵션으로는 웹캐스트 재생 및 특정 접근 코드를 통해 접근할 수 있는 전화 재생이 포함됩니다. 이 이벤트는 투자자와 애널리스트가 BioCardia의 최근 성과와 미래 전망에 대한 통찰력을 얻을 수 있는 기회를 제공합니다.
BioCardia (NASDAQ:BCDA), un développeur de thérapies cellulaires et dérivées pour des maladies cardiovasculaires et pulmonaires, a annoncé sa mise à jour d'entreprise et sa conférence téléphonique sur les résultats financiers du deuxième trimestre 2024. L'appel est prévu pour le 13 août 2024 à 16h30 ET. Les participants peuvent s'inscrire en ligne ou appeler pour rejoindre l'appel. Pour les appelants aux États-Unis, le numéro est 1-833-316-0559, tandis que les appelants internationaux doivent utiliser 1-412-317-5730. Une diffusion en direct sera également disponible. Les options de rediffusion incluent une rediffusion web et une rediffusion téléphonique accessibles avec des codes d'accès spécifiques. Cet événement offre aux investisseurs et aux analysts l'opportunité d'obtenir des informations sur la performance récente de BioCardia et ses perspectives d'avenir.
BioCardia (NASDAQ:BCDA), ein Entwickler von Zell- und zellbasierten Therapien für Herz-Kreislauf- und Lungenerkrankungen, hat seine Unternehmensaktualisierung und die telefonische Konferenz zu den Finanzberichten des zweiten Quartals 2024 angekündigt. Die Konferenz ist für 13. August 2024, um 16:30 Uhr ET geplant. Teilnehmer können sich online registrieren oder telefonisch an der Konferenz teilnehmen. Für Anrufer aus den USA lautet die Nummer 1-833-316-0559, während internationale Anrufer 1-412-317-5730 verwenden sollten. Es wird auch eine Live-Webcast verfügbar sein. Die Wiederholungsoptionen umfassen eine Webcast-Wiederholung und eine telefonische Wiederholung, die mit spezifischen Zugangscodes erreichbar sind. Diese Veranstaltung bietet Investoren und Analysten die Möglichkeit, Einblicke in die jüngsten Leistungen von BioCardia und die zukünftigen Aussichten zu erhalten.
- None.
- None.
SUNNYVALE, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three months ended June 30, 2024 by conference call on Tuesday, August 13, 2024 at 4:30 PM ET. Following management’s formal remarks, there will be a question-and-answer session.
Participants can register for the conference by navigating to https://dpregister.com/sreg/10191562/fd3d36338a. Please note that registered participants will receive their dial-in number upon registration. For those who have not registered, to listen to the call by phone, interested parties within the U.S. should call 1-833-316-0559 and international callers should call 1-412-317-5730. All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the BioCardia call. The conference call will also be available through a live webcast, which can be accessed through the following link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=BLDb4kwc
A webcast replay of the call will be available approximately one hour after the end of the call at the following link: https://services.choruscall.com/ccforms/replay.html. A telephonic replay of the call will be available and may be accessed by calling 1-877-344-7529 (domestic), 1-412-317-0088 (international) or 855-669-9658 (Canada) by using access code 6578627.
About BioCardia®
BioCardia, Inc., headquartered in Sunnyvale, California, is global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms. For more information visit www.biocardia.com.
FAQ
When is BioCardia's Q2 2024 earnings call scheduled?
How can investors participate in BioCardia's (BCDA) Q2 2024 conference call?
Will there be a replay available for BioCardia's (BCDA) Q2 2024 earnings call?
What is the focus of BioCardia's (BCDA) business?
